Bank of America Corporation Reaffirms Buy Rating for Becton, Dickinson and Company (NYSE:BDX)

Becton, Dickinson and Company (NYSE:BDX)‘s stock had its “buy” rating restated by stock analysts at Bank of America Corporation in a report released on Friday, July 21st. They presently have a $225.00 target price on the medical instruments supplier’s stock, up from their previous target price of $200.00. Bank of America Corporation’s price objective indicates a potential upside of 13.81% from the stock’s current price.

Other analysts also recently issued research reports about the company. Zacks Investment Research upgraded Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $225.00 target price for the company in a research report on Monday, July 17th. Jefferies Group LLC restated a “buy” rating and issued a $200.00 target price on shares of Becton, Dickinson and in a research report on Wednesday, March 29th. Royal Bank Of Canada restated a “hold” rating and issued a $177.00 target price on shares of Becton, Dickinson and in a research report on Thursday, April 13th. Evercore ISI upgraded Becton, Dickinson and from an “in-line” rating to an “outperform” rating and boosted their target price for the stock from $186.00 to $200.00 in a research report on Monday, April 24th. Finally, Cowen and Company restated an “outperform” rating and issued a $230.00 target price (up previously from $200.00) on shares of Becton, Dickinson and in a research report on Monday, July 10th. One analyst has rated the stock with a sell rating, five have given a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $195.79.

Becton, Dickinson and (NYSE:BDX) traded down 0.81% on Friday, hitting $197.69. 989,225 shares of the stock traded hands. The stock has a market cap of $44.99 billion, a P/E ratio of 57.25 and a beta of 1.05. The stock has a 50-day moving average price of $199.72 and a 200 day moving average price of $188.69. Becton, Dickinson and has a 12-month low of $161.29 and a 12-month high of $206.63.

Becton, Dickinson and (NYSE:BDX) last issued its quarterly earnings data on Thursday, August 3rd. The medical instruments supplier reported $2.46 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.44 by $0.02. Becton, Dickinson and had a return on equity of 22.53% and a net margin of 6.25%. The company had revenue of $3.04 billion during the quarter, compared to analyst estimates of $3.06 billion. During the same quarter in the previous year, the firm earned $2.35 earnings per share. Becton, Dickinson and’s revenue was down 5.1% on a year-over-year basis. On average, equities analysts expect that Becton, Dickinson and will post $9.46 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This news story was posted by BNB Daily and is the sole property of of BNB Daily. If you are reading this news story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be read at https://www.baseball-news-blog.com/2017/08/19/becton-dickinson-and-company-nysebdx-earns-buy-rating-from-bank-of-america-corporation-updated-updated-updated.html.

In other news, EVP Ribo Alberto Mas sold 7,463 shares of the company’s stock in a transaction on Monday, August 14th. The stock was sold at an average price of $201.41, for a total transaction of $1,503,122.83. Following the transaction, the executive vice president now directly owns 29,323 shares of the company’s stock, valued at $5,905,945.43. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Ellen R. Strahlman sold 9,283 shares of the company’s stock in a transaction on Thursday, August 10th. The shares were sold at an average price of $198.21, for a total value of $1,839,983.43. Following the transaction, the insider now directly owns 26,638 shares in the company, valued at $5,279,917.98. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 57,631 shares of company stock worth $11,112,178. 1.40% of the stock is owned by insiders.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. North Star Investment Management Corp. increased its position in shares of Becton, Dickinson and by 3.4% in the first quarter. North Star Investment Management Corp. now owns 549 shares of the medical instruments supplier’s stock worth $101,000 after buying an additional 18 shares during the last quarter. Crestwood Advisors Group LLC purchased a new position in Becton, Dickinson and during the first quarter worth $101,000. Almanack Investment Partners LLC. purchased a new position in Becton, Dickinson and during the first quarter worth $105,000. Parkside Financial Bank & Trust increased its position in Becton, Dickinson and by 1.4% in the first quarter. Parkside Financial Bank & Trust now owns 633 shares of the medical instruments supplier’s stock worth $116,000 after buying an additional 9 shares in the last quarter. Finally, Mitsubishi UFJ Securities Holdings Co. Ltd. increased its position in Becton, Dickinson and by 55.8% in the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 670 shares of the medical instruments supplier’s stock worth $131,000 after buying an additional 240 shares in the last quarter. 75.57% of the stock is currently owned by hedge funds and other institutional investors.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Analyst Recommendations for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply